{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-128616","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.359467+00:00","generated_at":"2026-06-16T05:10:38.819033+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pliant Therapeutics reports positive Phase 2a data for bexotegrast in IPF; FVC decline reduced 68% vs placebo","bullets":["Bexotegrast 320 mg well tolerated up to 40 weeks; no drug-related serious adverse events.","FVC decline reduced 68% vs placebo: mean FVCpp change -0.8% vs -2.5% at Week 24.","89% of patients with FVC increase at Week 12 maintained increase through Week 24.","QLF imaging showed fibrosis stabilization in bexotegrast group vs progression in placebo.","BEACON-IPF Phase 2b trial (160/320 mg, ~270 patients) to initiate in mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-128616","json":"https://secwatch.observer/filing/0001193125-23-128616.json","markdown":"https://secwatch.observer/filing/0001193125-23-128616.md","text":"https://secwatch.observer/filing/0001193125-23-128616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523128616/0001193125-23-128616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523128616/d440511d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:10:38.819033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}